Apyx Medical Files Routine 8-K; Confirms Nasdaq Listing
Ticker: APYX · Form: 8-K · Filed: Jan 22, 2024 · CIK: 719135
| Field | Detail |
|---|---|
| Company | Apyx Medical Corp (APYX) |
| Form Type | 8-K |
| Filed Date | Jan 22, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: administrative, corporate-governance, exchange-listing
TL;DR
**Apyx Medical filed a standard 8-K, mostly just updating basic company info and confirming its Nasdaq listing.**
AI Summary
Apyx Medical Corp filed an 8-K on January 22, 2024, to report 'Other Events' and 'Financial Statements and Exhibits.' This filing primarily updates administrative information, including the company's current name, address (5115 Ulmerton Road, Clearwater, Florida), and confirms its Class A common stock is traded on the Nasdaq Global Select Market under the symbol APYX. For investors, this filing is routine and doesn't signal any immediate operational or financial changes, but it confirms the company's current public trading status and basic corporate details.
Why It Matters
This filing is largely administrative, confirming Apyx Medical Corp's current corporate details and its listing on the Nasdaq Global Select Market, which is important for maintaining transparency and investor confidence.
Risk Assessment
Risk Level: low — This 8-K filing is administrative and does not contain information that indicates new or increased risks for investors.
Analyst Insight
A smart investor would note this as a routine administrative filing, confirming basic company information and trading status, but would not expect any immediate market-moving news from it. Further research into financial performance and strategic initiatives would be necessary for investment decisions.
Key Numbers
- January 22, 2024 — Date of Report (The date of the earliest event reported in this 8-K filing.)
- 001-31885 — Commission File Number (The SEC file number for Apyx Medical Corp.)
- 727-384-2323 — Issuer's telephone number (The primary contact number for Apyx Medical Corp.)
Key Players & Entities
- Apyx Medical Corp (company) — the registrant filing the 8-K
- Nasdaq Global Select Market (company) — the exchange where Apyx Medical's Class A common stock is registered
- 5115 Ulmerton Road, Clearwater, Florida 33760 (dollar_amount) — Apyx Medical Corp's principal executive offices address
- January 22, 2024 (dollar_amount) — date of earliest event reported and filing date
- 001-31885 (dollar_amount) — Commission File Number for Apyx Medical Corp
- APYX (company) — trading symbol for Apyx Medical Corp's Class A common stock
Forward-Looking Statements
- Apyx Medical Corp will continue to trade on the Nasdaq Global Select Market. (Apyx Medical Corp) — high confidence, target: 2025-01-22
- No major corporate structure changes will be announced in the immediate future based on this filing. (Apyx Medical Corp) — high confidence, target: 2024-04-22
FAQ
What is the primary purpose of this 8-K filing by Apyx Medical Corp?
The primary purpose of this 8-K filing by Apyx Medical Corp, dated January 22, 2024, is to report 'Other Events' and 'Financial Statements and Exhibits,' which in this case, primarily involves updating administrative information and confirming its trading status.
On which stock exchange is Apyx Medical Corp's Class A common stock registered?
Apyx Medical Corp's Class A common stock is registered on the Nasdaq Global Select Market, as stated in the filing under 'Securities registered pursuant to Section 12(b) of the Act'.
What is the trading symbol for Apyx Medical Corp's Class A common stock?
The trading symbol for Apyx Medical Corp's Class A common stock is APYX, as indicated in the filing under 'Title of each class' and 'Trading Symbol(s)'.
What is the business address of Apyx Medical Corp as listed in this filing?
The business address of Apyx Medical Corp is 5115 Ulmerton Road, Clearwater, Florida 33760, according to the 'BUSINESS ADDRESS' section of the filing.
Did Apyx Medical Corp report any significant operational or financial changes in this 8-K?
No, this 8-K filing does not report any significant operational or financial changes. It is primarily an administrative update, confirming corporate details and trading information, under 'Other Events' and 'Financial Statements and Exhibits'.
Filing Stats: 431 words · 2 min read · ~1 pages · Grade level 12 · Accepted 2024-01-22 08:13:58
Filing Documents
- apyx-20240122.htm (8-K) — 25KB
- apyxex991studypressrelease.htm (EX-99.1) — 15KB
- apyx-20240122_g1.jpg (GRAPHIC) — 21KB
- image2.jpg (GRAPHIC) — 79KB
- 0000719135-24-000005.txt ( ) — 321KB
- apyx-20240122.xsd (EX-101.SCH) — 2KB
- apyx-20240122_lab.xml (EX-101.LAB) — 24KB
- apyx-20240122_pre.xml (EX-101.PRE) — 12KB
- apyx-20240122_htm.xml (XML) — 3KB
01 - Other Events
Item 8.01 - Other Events On January 22, 2024, Apyx Medical Corporation (the "Company") issued a press release announcing the publication of a peer-reviewed clinical publication evaluating the safety of Renuvion for contracting subcutaneous soft tissue following liposuction in multiple areas of the body. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.
01 - Financial Statements and Exhibits
Item 9.01 - Financial Statements and Exhibits (d) Exhibit No. Description 99.1 Press release dated January 22, 2024
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 22, 2024 Apyx Medical Corporation By: /s/ Matthew Hill Matthew Hill Chief Financial Officer, Secretary and Treasurer